DenMat now handling global distribution of VELscope Vx

November 6, 2012

The VELscope oral cancer screening system has made an impact on the dental industry since its original VELscope Vantage System was introduced in 2008. A much smaller version using natural tissue fluorescence to discover abnormalities in the oral mucus, including oral cancer, was released last year and was well received.  

The VELscope oral cancer screening system has made an impact on the dental industry since its original VELscope Vantage System was introduced in 2008. A much smaller version using natural tissue fluorescence to discover abnormalities in the oral mucus, including oral cancer, was released last year and was well received.
 
In fact, the VELscope Vx® was honored in the DPR December 2011 issue as one of the 10 Top Upgraded & Updated products. Now, DenMat Holdings LLC has announced that it has entered into a long-term exclusive agreement with LED Medical Diagnostics Inc. as the exclusive global distributor (except for a handful of group practices for a limited time) for the VELscope Vx, including all responsibility for sales and marketing. As the most powerful technology available for assisting in the discovery of oral mucosal abnormalities, VELscope Vx plays a key role in the early discovery of such abnormalities, which can be critically important in the fight against oral cancer.
 
"We were seeking a partner that not only has a direct relationship with the dental market, but one with the experience and knowledge to bring VELscope Vx to more dentists and their patients," said Peter Whitehead, LED’s founder and CEO. "DenMat has the experienced team and the proven track record with leading-edge technologies to be our ideal partner in communicating the importance of this powerful system."
 
Detecting tissue abnormalities as early as possible is potentially life-saving, and VELscope Vx technology is proven effective and minimally invasive, and seamlessly can be implemented in a patient's routine dental check-ups.
 
"LED is a recognized leader and innovator in providing dentists with powerful clinical technologies,” said Robert Cartagena, DenMat’s Chief Operating Officer. “DenMat shares LED’s commitment to the early detection of lesions and tissue abnormalities. This is potentially critical information for clinicians, and DenMat is positioned to carry forward the banner of early detection to the worldwide dental profession."
 
VELscope Vx's distinctive blue-spectrum light causes the soft tissues of the mouth to naturally fluoresce. Healthy tissues fluoresce in distinct patterns that are visibly disrupted by trauma or disease. Use of the VELscope Vx allows a wide variety of oral abnormalities to be discovered, often before they're visible to the unassisted eye.
 
"Giving clinicians the power to see potentially life-threatening abnormalities brings a new dimension to patient care, one which we are committed to advancing on a global scale," Cartagena said.
 
For more information about VELscope Vx, contact DenMat at 805-433-6628 or visit the website.